Olympus Corporation has entered into an exclusive global distribution agreement with EndoRobotics to commercialise robot-assisted endoscopic technologies as part of its EndoTherapy portfolio. The collaboration is designed to accelerate the adoption of advanced minimally invasive procedures, particularly in the treatment of gastrointestinal (GI) diseases.

Under the agreement, Olympus will leverage its global commercial infrastructure to distribute EndoRobotics’ technologies across international markets, beginning with the United States. The partnership combines Olympus’ expertise in endoscopy-enabled care with EndoRobotics’ innovation in next-generation therapeutic robotics.

The collaboration is expected to enhance the precision, control and efficiency of complex procedures such as Endoscopic Submucosal Dissection (ESD), which is used to treat early-stage cancers and precancerous lesions of the GI tract. By enabling organ-sparing interventions, ESD allows physicians to remove diseased tissue without the need for major surgery, reducing procedural risks, minimising complications and shortening recovery time for patients.

As the global incidence of GI cancers continues to rise, demand for advanced and consistent treatment outcomes is increasing. Robot-assisted technologies are playing a growing role in addressing these challenges by supporting clinicians in performing intricate procedures with greater confidence and accuracy.

The agreement reflects Olympus’ broader strategy to advance endoluminal robotics and expand patient access to innovative therapeutic solutions. At the same time, the company continues to invest in long-term platform development aimed at transforming endoscopy-enabled care.

EndoRobotics, known for its focus on developing robotic solutions for therapeutic endoscopy, will contribute its technological expertise to support the global rollout. The company aims to improve patient outcomes by enabling faster treatment, quicker recovery and broader access to minimally invasive care.

Further details regarding product availability and regional launches will be announced in line with regulatory approvals and market requirements.